Hebrew University of Jerusalem, Immune Pharmaceuticals deal
Yissum, the tech transfer arm of the university, granted Immune exclusive, worldwide rights to patents covering a topical nano-formulated version of AmiKet to treat neuropathic pain. Yissum is eligible to receive up to $4.5 million in regulatory, development and commercialization milestones.
Specifically, Yissum will receive $60,000 upon IND submission; $400,000 upon FDA accepting an IND; $90,000 for enrolling a patient in a Phase I trial; $250,000 for enrolling a patient in a Phase II trial; $500,000 for enrolling a patient in a Phase III trial; $200,000 upon acceptance of an MAA in Europe, the Middle East or Africa; $2 million upon the first commercial sale in the U.S.; and $1 million upon the first commercial sale in the EU. Yissum is eligible for up to 3% royalties. Yissum will also receive an annual maintenance fee beginning in 2020 and a $400,000 annual research fee. ...